Stem Cell Differentiation Using Defined Serum-Free Medium
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating human pluripotent stem cells into CD34+ progenitor cells are inefficient, laborious, and often require the use of animal-derived materials or the formation of embryoid bodies, which can lead to variable results and regulatory issues.
Innovation Solution
A method using a defined differentiation medium free from feeder cells and serum, with specific atmospheric conditions, including hypoxic oxygen levels, to differentiate pluripotent stem cells into CD34+, CD31+, or CD43+ progenitor cells, utilizing recombinant growth factors like BMP-4, VEGF, and bFGF, and matrix components such as fibronectin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If embryoid bodies are used to induce differentiation, then multiple tissue types can be generated, but the process becomes inefficient and laborious with complex automation difficulties
Solution Approach 1:
The patent extracts and eliminates the embryoid body formation step from the differentiation process. By directly differentiating pluripotent stem cells on monolayer culture without forming three-dimensional embryoid bodies, the method removes the inefficient aggregation and dissociation steps while still achieving differentiation into multiple tissue types including hematopoietic and endothelial lineages
Solution Approach 2:
The patent segments the differentiation process into distinct temporal phases with specific growth factor combinations. The method uses sequential addition or removal of growth factors (BMP4, VEGF, bFGF) at different time points to guide differentiation through specific stages, allowing controlled generation of multiple lineages without embryoid body formation
2Reliability
If mouse feeder cells are used for co-culture, then cell growth is supported, but the risk of unexpected transformations and interspecies exposure increases
Solution Approach 1:
The patent completely removes mouse feeder cells from the culture system. By using defined serum-free media with recombinant growth factors and human cell-derived conditioned media, the method eliminates interspecies exposure while maintaining reliable cell growth and differentiation support through chemically defined components
Solution Approach 2:
The patent introduces human cell-derived conditioned media as an intermediary to provide growth support. Conditioned media from human endothelial cells or human embryonic stem cells replaces mouse feeder cells, providing necessary growth factors and signaling molecules while eliminating interspecies contamination risks
3Quantity of substance
If serum is used in differentiation medium, then nutrients are provided, but batch-to-batch variability and regulatory issues arise
Solution Approach 1:
The patent changes the chemical composition parameters of the differentiation medium by replacing serum with defined components. The method uses serum-free media with precisely controlled concentrations of recombinant growth factors (BMP4, VEGF, bFGF), amino acids, vitamins, and minerals, eliminating the variability inherent in animal serum batches
Solution Approach 2:
The patent creates a composite defined medium formulation combining multiple purified components. The serum-free differentiation medium integrates recombinant growth factors, defined amino acid mixes, vitamin formulations, and buffered salts in specific ratios, providing consistent nutrient provision without serum-related variability
Data Source
AI summary
The present invention provides methods and compositions for the production of hematopoietic progenitor cells or endothelial progenitor cells from human pluripotent stem cells using a defined cell culture medium without the need to utilize feeder cells or serum. In some embodiments, differentiation is accomplished using hypoxic atmospheric conditions. The defined medium of the present invention may contain growth factors and a matrix component. The hematopoietic progenitor cells may be further differentiated into cell lineages including red blood cells, macrophages, granulocytes, and megakaryocytes. The endothelial progenitor cells may be further differentiated into endothelial cells. Also disclosed are screening assays for identification of candidate substances that affect differentiation of pluripotent stem cells into progenitor cells.